Literature DB >> 8037206

The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel.

O N Elpeleg1, Y Anikster, V Barash, D Branski, A Shaag.   

Abstract

Canavan disease (CD) is an infantile neurodegenerative disease that is transmitted in an autosomal recessive manner and has mainly been reported in Ashkenazi Jewish families. The primary enzymatic defect is aspartoacylase deficiency, and an A-to-C transition at nucleotide 854 of the cDNA has recently been reported. We screened 18 patients with CD and 879 healthy individuals, all Israeli Ashkenazi Jews, for the mutation. All 18 patients were homozygotes for the mutation, and 15 heterozygotes were found among the healthy individuals. The results disclose a carrier rate of 1:59 and suggest that a screening for the mutation is warranted among Ashkenazi Jewish couples.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037206      PMCID: PMC1918378     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population.

Authors:  D Abeliovich; I P Lavon; I Lerer; T Cohen; C Springer; A Avital; G R Cutting
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

2.  N-acetylaspartic aciduria: report of three new cases in children with a neurological syndrome associating macrocephaly and leukodystrophy.

Authors:  P Divry; C Vianey-Liaud; C Gay; V Macabeo; F Rapin; B Echenne
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

3.  Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.

Authors:  R Matalon; K Michals; D Sebesta; M Deanching; P Gashkoff; J Casanova
Journal:  Am J Med Genet       Date:  1988-02

4.  Protracted clinical course for patients with Canavan disease.

Authors:  N Zelnik; A S Luder; O N Elpeleg; V Gross-Tsur; N Amir; J A Hemli; A Fattal; S Harel
Journal:  Dev Med Child Neurol       Date:  1993-04       Impact factor: 5.449

5.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

Authors:  E Beutler; N J Nguyen; M W Henneberger; J M Smolec; R A McPherson; C West; T Gelbart
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

6.  Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.

Authors:  R Kaul; G P Gao; K Balamurugan; R Matalon
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

7.  Spongy degeneration of the brain in Israel: a retrospective study.

Authors:  M Ungar; R M Goodman
Journal:  Clin Genet       Date:  1983-01       Impact factor: 4.438

  7 in total
  10 in total

1.  The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.

Authors:  O N Elpeleg; A Shaag
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.

Authors:  R Kaul; G P Gao; R Matalon; M Aloya; Q Su; M Jin; A B Johnson; R B Schutgens; J T Clarke
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

3.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

4.  A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family.

Authors:  Rashida Hussain; Shakeela Daud; Naseebullah Kakar; Adeel Ahmad; Abdul Hameed Baloch; Abdul Malik Tareen; Muhammad Azam Kakar; Jamil Ahmad
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

5.  Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Authors:  Eduard Bitto; Craig A Bingman; Gary E Wesenberg; Jason G McCoy; George N Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

6.  Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population.

Authors:  D Kronn; C Oddoux; J Phillips; H Ostrer
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

7.  Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis.

Authors:  O N Elpeleg; A Shaag; Y Anikster; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

8.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

9.  The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients.

Authors:  A Shaag; Y Anikster; E Christensen; J Z Glustein; A Fois; H Michelakakis; F Nigro; E Pronicka; A Ribes; M T Zabot
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

10.  Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.

Authors:  B J Zeng; Z H Wang; L A Ribeiro; P Leone; R De Gasperi; S J Kim; S Raghavan; E Ong; G M Pastores; E H Kolodny
Journal:  J Inherit Metab Dis       Date:  2002-11       Impact factor: 4.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.